The Medical Letter on Drugs and Therapeutics
When a Statin Fails
The full article is available to subscribers Subscriber Login   
Revised 8/5/09: The first paragraph should have included the words "for patients at high risk" after 100 mg/dL (2.6 mmol/L).

The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) for patients at high risk and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.

LDL-C TARGETS —A meta-analysis of 58 placebo-controlled, lipid-lowering trials showed that statins reduced ischemic heart disease events by 20%, 31% and 51% when mean reductions of LDL-C were 20 mg/dL (0.5 mmol/L), 40 mg/dL (1.0 mmol/L) and 62 mg/dL (1.6 mmol/L) respectively, and reduced strokes by 10% and 17% when LDL-C was lowered by 40 mg/dL (1.0 mmol/L) and 70 mg/dL (1.8 mmol/L) respectively.1 In a controlled trial, 2 years of treatment with 40 mg of rosuvastatin (Crestor) reduced LDL-C by 53% to 61 mg/dL and led to significant regression of coronary atherosclerosis.2


The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: When a Statin Fails
Article code: 1317c
 Electronic, downloadable article - $25